Foghorn Therapeutics (FHTX) Capital Expenditures (2019 - 2026)

Foghorn Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $35000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 25.0% year-over-year to $35000.0; the TTM figure through Mar 2026 stood at $57000.0 (down 93.16% YoY), while the FY2025 annual figure was $50000.0, down 94.48% from the prior year.
• Capital Expenditures was $35000.0 for Q1 2026 at Foghorn Therapeutics, down from $50000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q3 2023 to a low of -$1.2 million in Q4 2023.
• Historically, Capital Expenditures has averaged $131529.4 across 5 years, with a median of $50000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 236.25% in 2022, then slumped 528.25% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $269000.0 in 2022, then plunged by 528.25% to -$1.2 million in 2023, then surged by 153.56% to $617000.0 in 2024, then slumped by 91.9% to $50000.0 in 2025, then retreated by 30.0% to $35000.0 in 2026.
• The last three Capital Expenditures figures came in at $35000.0 (Q1 2026), $50000.0 (Q4 2025), and -$50000.0 (Q3 2025), per Business Quant data.